Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Beyond right to try

Even without right to try, patients may get better access to unapproved drugs

May 5, 2017 10:55 PM UTC

Enacting a federal right-to-try law that circumvents FDA’s oversight of access to unapproved therapies no longer looks like a sure bet. Still, the debate over right to try has stimulated initiatives to give more patients who have run out of alternatives the chance to try experimental drugs and medical devices.

Propelled by victories in 34 states and endorsement of their cause by President Donald Trump, Vice President Mike Pence and 46 senators, patient advocates and libertarian activists pushing for federal right-to-try (RTT) legislation believed in January that victory in Congress was imminent. Like other populists who swept into the nation’s capital, they’ve learned that nothing in Washington is as simple as it seems. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article